Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 The distribution of benign ovarian tumors and BOTs including subgroup of BOTs by age, menopausal status, ultrasound score, serum CA125, and tumor size

From: Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors

Variables Benign (n = 379) BOTs (n = 162) P value SBOT P value MBOT P value
Age (years)
Mean ± SD
37.73 ± 14.61 40.3 ± 15.12 0.065b 39.88 ± 14.32 0.168b 41.24 ± 16.92 0.12b
Menopausal status    0.88c   0.77c   0.438c
 Premenopausal 297 126   90   36  
 Postmenopausal 82 36   23   13  
Ultrasound scorea n, (%)    N/Ac   N/Ac   N/Ac
 0 159(42) 12 (7.4)   9   3  
 1 187(49.3) 81 (50)   53   28  
 2–5 33 (8.7) 69(42.6)   51   18  
CA 125 (U/mL)
Mean ± SD
34.77 ± 6.16 192.15 ± 98.13 N/Ad 235.63 ± 322.28 N/Ad 91.8 ± 202.61 N/Ad
Tumor size (cm)    N/Ac   0.505c   N/Ac
 <7 198 58   55   3  
 ≥7 181 104   58   46  
  1. aUltrasound scores were recorded as one point for each of the following characteristics: multilocularity, solid areas, bilaterality, ascites and intra-abdominal metastases
  2. bStudent’s t-test
  3. cChi square test
  4. dMann–Whitney U test